Jove
Visualize
Contact Us

Related Concept Videos

Principles of Disease Surveillance01:26

Principles of Disease Surveillance

565
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
565
Immune Surveillance by NK Cells and Phagocytes01:25

Immune Surveillance by NK Cells and Phagocytes

8.8K
Immune surveillance is an integral part of the innate immune system, involving the continuous monitoring of peripheral tissues to detect and respond to pathogens, infected cells, or cancerous cells. This surveillance is conducted primarily by natural killer (NK) cells and phagocytes, which employ distinct but complementary mechanisms to identify and eliminate threats.
Natural Killer Cells: The Fast Responders
NK cells are large granular lymphocytes found in the blood and lymphatic system. These...
8.8K
SN1 Reaction: Stereochemistry02:15

SN1 Reaction: Stereochemistry

10.4K
This lesson provides an in-depth discussion of the stereochemical outcomes in an SN1 reaction.
In the first step of an SN1 reaction, the bond between the electrophilic carbon and the leaving group ionizes to generate the carbocation intermediate. The second step of the mechanism is the nucleophilic attack.
In the formed carbocation, the positively charged carbon is sp2 hybridized with a trigonal planar geometry. As all the three substituents lie on the same plane, a plane of symmetry for the...
10.4K
SN1 Reaction: Kinetics02:05

SN1 Reaction: Kinetics

9.6K
In an SN2 reaction, the reaction rate depends on both the type of nucleophile and the substrate. A hindered tertiary alkyl halide is practically inert to the SN2 mechanism despite using a strong nucleophile.
However, Sir Christopher Ingold and Edward D. Hughes, who studied the kinetics of various nucleophilic substitution reactions, noticed that a tertiary alkyl halide does undergo a nucleophilic substitution reaction in the presence of a weak nucleophile. While studying the substitution...
9.6K
SN1 Reaction: Mechanism02:25

SN1 Reaction: Mechanism

14.4K
Kinetic studies of ionization of a tertiary halide in a protic solvent suggest that only the substrate participates in the rate-determining step (slow step). The nucleophile is involved only after the slowest step. The SN1 reaction takes place in a multiple-step mechanism. 
Firstly, the haloalkane ionizes to generate a carbocation intermediate and a halide ion. This heterolytic cleavage is highly endothermic with large activation energy. The ionization of the substrate, facilitated by a...
14.4K
Acidity of 1-Alkynes02:42

Acidity of 1-Alkynes

11.3K

The acidic strength of hydrocarbons follows the order: Alkynes > Alkenes > Alkanes. The strength of an acid is commonly expressed in units of pKa — the lower the pKa, the stronger the acid. Among the hydrocarbons, terminal alkynes have lower pKa values and are, therefore, more acidic. For example, the pKa values for ethane, ethene, and acetylene are 51, 44, and 25, respectively, as shown here.
11.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Invasive pneumococcal disease in Australia: 2013 and 2014.

Communicable diseases intelligence (2018)·2025
Same author

Retrospective analysis of multidrug-resistant tuberculosis case notifications in Australia (1999-2018).

Communicable diseases intelligence (2018)·2020
Same author

Invasive Pneumococcal Disease Surveillance, 1 April to 30 June 2019.

Communicable diseases intelligence (2018)·2020
Same author

Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2019.

Communicable diseases intelligence (2018)·2020
Same author

Invasive Pneumococcal Disease Surveillance, 1 July to 30 September 2018.

Communicable diseases intelligence (2018)·2019
Same author

Invasive Pneumococcal Disease Surveillance, 1 January to 31 March 2018.

Communicable diseases intelligence (2018)·2019
Same journal

National Notifiable Diseases Surveillance System, 1 October to 31 December 2017.

Communicable diseases intelligence quarterly report·2018
Same journal

National Notifiable Diseases Surveillance System, 1 July to 30 September 2017.

Communicable diseases intelligence quarterly report·2018
Same journal

National Notifiable Diseases Surveillance System, 1 April to 30 June 2017.

Communicable diseases intelligence quarterly report·2018
Same journal

OzFoodNet quarterly report, 1 July to 30 September 2015.

Communicable diseases intelligence quarterly report·2018
Same journal

OzFoodNet quarterly report, 1 April to 30 June 2015.

Communicable diseases intelligence quarterly report·2018
Same journal

The Australian Sentinel Practices Research Network, 1 January to 31 March 2017.

Communicable diseases intelligence quarterly report·2018
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Feb 9, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.3K

Invasive Pneumococcal Disease Surveillance, 1 April to 30 June 2017.

Kate Pennington1,

  • 1Communicable Disease Epidemiology and Surveillance Section , Office of Health Protection, Australian Government Department of Health.

Communicable Diseases Intelligence Quarterly Report
|June 5, 2018
PubMed
Summary
This summary is machine-generated.

Invasive pneumococcal disease (IPD) cases rose in Q2 2017. While the 13-valent pneumococcal conjugate vaccine (13vPCV) initially reduced disease, non-vaccine serotypes are now increasing.

More Related Videos

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

13.1K
Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan
07:55

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Published on: August 27, 2019

8.0K

Related Experiment Videos

Last Updated: Feb 9, 2026

Experimental Human Pneumococcal Carriage
07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

16.3K
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
09:20

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay

Published on: April 28, 2014

13.1K
Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan
07:55

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Published on: August 27, 2019

8.0K

Area of Science:

  • Public Health
  • Epidemiology
  • Vaccinology

Background:

  • The 7-valent pneumococcal conjugate vaccine (7vPCV) was replaced by the 13-valent pneumococcal conjugate vaccine (13vPCV) in the childhood immunization program in July 2011.
  • This vaccine switch aimed to broaden protection against more pneumococcal serotypes.

Observation:

  • Notified cases of invasive pneumococcal disease (IPD) increased in the second quarter of 2017 compared to the previous quarter and the same quarter in 2016.
  • Following the introduction of 13vPCV, there was an initial rapid decline in IPD cases due to the six additional serotypes covered by 13vPCV.
  • The rate of decline in IPD cases has slowed in recent years.

Findings:

  • Cases due to serotypes covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV) but not 13vPCV have been steadily increasing.
  • Cases due to pneumococcal serotypes not covered by any available vaccine have also shown a steady increase across all age groups.
  • These trends suggest a potential shift in the dominant circulating serotypes and the emergence of non-vaccine-type IPD.

Implications:

  • The findings highlight the dynamic nature of invasive pneumococcal disease epidemiology following vaccine introduction.
  • There is a need for ongoing surveillance to monitor serotype distribution and vaccine effectiveness.
  • This information is crucial for informing public health strategies and potential vaccine updates to address evolving pneumococcal resistance patterns.